Kast, Florian http://orcid.org/0000-0001-5586-8382
Schwill, Martin http://orcid.org/0000-0002-2798-5490
Stüber, Jakob C. http://orcid.org/0000-0002-3406-0664
Pfundstein, Svende
Nagy-Davidescu, Gabriela
Rodríguez, Josep M. Monné
Seehusen, Frauke
Richter, Christian P.
Honegger, Annemarie http://orcid.org/0000-0002-3378-3967
Hartmann, Karen Patricia
Weber, Thomas G.
Kroener, Felix
Ernst, Patrick http://orcid.org/0000-0001-6037-1856
Piehler, Jacob
Plückthun, Andreas http://orcid.org/0000-0003-4191-5306
Article History
Received: 4 July 2020
Accepted: 25 May 2021
First Online: 18 June 2021
Competing interests
: The authors (Florian K, MS, JCS, AH and AP) filed the following patents relating to the described bispecific antibodies: Bispecific HER2 Ligands for Cancer Therapy [US20190127481A1; published]; inventors: A.P., F.Ka., M.S., A.H., Rastislav Tamaskovic, Christian Jost; current assignee: University of Zurich. Her2-binding tetrameric polypeptides [EP3733714; published]; inventors: F.Ka., M.S., A.H., J.C.S., Rastislav Tamaskovic, A.P.; current assignee: University of Zurich. The University of Zurich has licensed out the invention to Innovent Biologics, Inc. The other authors declare no competing interests.